Metraipolis › archive › dc_e9150bdd993c
Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study — Europe PMC PMID:42071878
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42071878
- DOI
- 10.1097/md.0000000000048470
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T14:05:06.976Z
- SHA-256 of the archived text
ff4a85dcb19809c27e78eb66655a970b1a111477ec60983cdd3074f9e9133a6d- Stable URL of this page
https://metraipolis.com/documento/dc_e9150bdd993c
How to cite
Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study — Europe PMC PMID:42071878 — Europe PMC (en), https://europepmc.org/article/MED/42071878 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e9150bdd993c (Metraipolis archive dc_e9150bdd993c, sha256 ff4a85dcb19809c27e78eb66655a970b1a111477ec60983cdd3074f9e9133a6d)
BibTeX
@misc{dce9150bdd993c,
title = {Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study — Europe PMC PMID:42071878},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42071878},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e9150bdd993c; sha256 ff4a85dcb19809c27e78eb66655a970b1a111477ec60983cdd3074f9e9133a6d},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42071878. Agents can read the archived copy with the MCP tool read_document.